The Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California. File picture: Mike Blake/Reuters
The Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California. File picture: Mike Blake/Reuters

Study shows Gilead's remdesivir slows disease progression in monkeys with Covid-19

By Reuters Time of article published Jun 9, 2020

Share this article:

Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaques infected with the new coronavirus, according to a study published in medical journal Nature on Tuesday.

Remdesivir has been cleared for emergency use in severely-ill patients in the United States, India and South Korea. Some European nations are also using it under compassionate programs.

Trials of the drug in humans are ongoing, and early data has shown the drug helped patients recover more quickly from the illness caused by the new coronavirus.

In the study, 12 monkeys were deliberately infected with the coronavirus, and half of them were given early treatment with remdesivir.

A lab technician visually inspects a filled vial of investigational remdesivir at a Gilead Sciences facility. Picture: Reuters

Macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors. 

Reuters

Share this article: